Elestrin

Elestrin is a brand name of estradiol, approved by the FDA in the following formulation(s):

ELESTRIN (estradiol - gel, metered; transdermal)

• 
  Manufacturer: AZUR PHARMA II
  
  Approval date: December 15, 2006
  
  Strength(s): 0.06% (0.87GM/ACTIVATION) ^[RLD]

Has a generic version of Elestrin been approved?

No. There is currently no therapeutically equivalent version of Elestrin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elestrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Formulations for transdermal or transmucosal application
  Patent 7,198,801
  Issued: April 3, 2007
  Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
  Assignee(s): Antares Pharma IPL AG
  The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
  
  Patent expiration dates:
  
  
  • June 25, 2022
    
    ✓ 
    Drug product
  
  



• 
  Formulations for transdermal or transmucosal application
  Patent 7,470,433
  Issued: December 30, 2008
  Inventor(s): Carrara; Dario Norberto R. & Grenier; Arnaud & Besse; Celine & Simes; Stephen M. & Lehman; Leah M.
  Assignee(s): Antares Pharma IPL AG
  The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
  
  Patent expiration dates:
  
  
  • August 3, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Elestrin Consumer Information (Drugs.com)
• Elestrin Gel Consumer Information (Wolters Kluwer)
• Elestrin Pump for use on skin Consumer Information (Cerner Multum)
• Elestrin for use on skin Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)